நாடவ் ஃபிரைட்மேன் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from நாடவ் ஃபிரைட்மேன். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In நாடவ் ஃபிரைட்மேன் Today - Breaking & Trending Today

Cassava Sciences Announces Positive Cognition Data With Simufilam in Alzheimer's Disease

Cassava Sciences Announces Positive Cognition Data With Simufilam in Alzheimer's Disease
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.

United States , Nadav Friedmann , Lindsay Burns , Eric Schoen , Cassava Sciences Inc , Company Phase , Alzheimer Association International Conference , National Institutes Of Health , Alzheimer Disease International , Neuroscience At Cassava Sciences , Cassava Sciences , Cassava Sciences Announce Positive Biomarker Data , Pfizer Global Research , Simufilam Significantly Improves Cognition , Interim Analysis , Open Label Study , Improvements Track , Behavior Disorders , Behavior Suggest Highly Encouraging Treatment , Sciences Inc , National Institutes , Neuropsychiatric Inventory , Chief Medical , Sciences Announce Positive Biomarker Data , About Today Oralpresentation , Association International Conference ,

Cassava Sciences Announces Positive Cognition Data With Simufilam in Alzheimer's Disease

Cassava Sciences Announces Positive Cognition Data With Simufilam in Alzheimer's Disease
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

Nadav Friedmann , Eric Schoen , Cassava Sciences Inc , Alzheimer Disease International , Company Phase , National Institutes Of Health , Cassava Sciences , Cassava Sciences Announce Positive Biomarker Data , Simufilam Significantly Improves Cognition , Interim Analysis , Open Label Study , Neuropsychiatric Inventory , Chief Medical , Sciences Announce Positive Biomarker Data , Encouraging Interim Results , National Institutes , Biological Chemistry , Disease International , More Information Contact , Chief Financial Officer , Note Regarding Forward Looking Statements , Private Securities Litigation Reform Act , Annual Report , நாடவ் ஃபிரைட்மேன் , எரிக் ஸ்கோன் , கசவா அறிவியல் இன்க் ,

Cassava Sciences' Simufilam Improves Cognition and Behavior in Alzheimer's Disease in Interim ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Cassava Sciences’ Simufilam Improves Cognition and Behavior in Alzheimer’s Disease in Interim .
Cassava Sciences, Inc.February 2, 2021 GMT
- Patients’ Cognition Improved 1.6 Points on ADAS-Cog11 -
- Patients’ Behavior Improved 1.3 Points on NPI -
- Improvements Maintained at 6 Months -
- Results Support Advancing Simufilam into Phase 3 Clinical Program -
AUSTIN, Texas, Feb. 02, 2021 (GLOBE NEWSWIRE) Cassava Sciences, Inc. (Nasdaq: SAVA) today announced results of an interim analysis from an open-label study of simufilam, its lead drug candidate for the treatment of Alzheimer’s disease. Patients’ cognition and behavior scores both improved following six months of simufilam treatment, with no safety issues. ....

United States , Nadav Friedmann , Remi Barbier , Eric Schoen , Cassava Sciences Inc , Cassava Sciences , National Institutes Of Health , Drug Administration , Clinical Program , Cassava Sciences Safe Harbor , Cognition Improved , Behavior Improved , Support Advancing Simufilam , National Institutes , Neuropsychiatric Inventory , Chief Medical , Interim Analysis , Disease Assessment Scale Cognitive Subscale , Mini Mental State Exam , Biological Chemistry , More Information Contact , Chief Financial Officer , Private Securities Litigation Reform Act , Annual Report , ஒன்றுபட்டது மாநிலங்களில் , நாடவ் ஃபிரைட்மேன் ,